

## **Subcommittee on Antimicrobial Susceptibility Testing - 2017 Disclosure Summary**

### **Personal, Professional, and Financial Interests**

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities (from past 3 years).

**Melvin P. Weinstein, MD - Chairholder**  
**Rutgers Robert Wood Johnson Medical School**

Financial Interests or Benefits:

Research support 2014-2016: Beckman Coulter, BD, JMI Labs, NJDOH

Research/speaker honorarium: T2 Biosystems

Consultant: Accelerate Diagnostics

**Jean B. Patel, PhD, D(ABMM) - Vice-Chairholder**  
**Centers for Disease Control and Prevention**

Financial Interests or Benefits: None

**Richard B. Thomson, Jr., PhD - Chairholder, Microbiology Expert Panel**  
**Evanston Hospital, NorthShore University HealthSystem**

Financial Interests or Benefits: Received honoraria, consulting fees or research funding in the past three years from International Health Management Associates, BD Kiestra, Nanosphere, and 5 not-for-profit universities and microbiology societies.

**Mary Jane Ferraro, PhD, MPH, Vice Chairholder, Microbiology Expert Panel**  
**Massachusetts General Hospital**

Financial Interests or Benefits: Research grants to institution from bioMerieux and BD.

### **Members**

**George M. Eliopoulos, MD**  
**Beth Israel Deaconess Medical Center**

Financial Interests or Benefits:

Advisory Boards - Bayer, Durata, Nabriva, Paratek, Rempex, and Theravance

Consultation - Shionogi

**Marcelo Galas**  
**Pan American Health Organization**  
Financial Interests or Benefits: None

**Romney M Humphries, PhD D(ABMM)**  
**UCLA David Geffen School of Medicine**

Financial Interests or Benefits:

Research grants to institution- bioMerieux, Beckman Coulter, GenMark, Curetis, BD, Accelerate Diagnostics, Applied BioCode, Merck, Allergan

Speaker Honorarium - Merck, Allergan

Advisory Board - Luminex, Roche, Cepheid, MicrobeDx, Allergan, Merck, DNAe, ThermoFisher

**Stephen G. Jenkins, PhD, D(ABMM),F(AAM)**  
**New York Presbyterian Hospital**

Financial Interests or Benefits:

Advisory boards for Bayer, Cempra, Cormedix, Insmmed, and Merck.

**James S. Lewis, II, PharmD, FIDSA**  
**Oregon Health & Science University**

Financial Interests or Benefits:

Consultant for - Accelerate Diagnostics, Achaogen, Allergan, Merck, Medicines Company, Paratek, Shinogi, and Theravance

**Brandi Limbago, PhD**  
**Centers for Disease Control and Prevention**

Financial Interests or Benefits: None

**Amy Mathers, MD**  
**University of Virginia Medical Center**

Financial Interests or Benefits:

Research: Rempex Pharmaceuticals

Consultant for Rempex Pharmaceuticals, Accelerate Diagnostics

**Tony Mazzulli, MD, FRCP(C), FACP**  
**Mount Sinai Hospital**

Financial Interests or Benefits:

President: Canadian Association of HIV Clinical Laboratory Specialists

Speaker Honorarium: Abbott, Merck, Roche

Advisory Board: bioMerieux, Qvella Corporation, Pfizer, Roche, Merck, Microbix

Research Funding: Biomerieux, Qvella

Member, Executive Committee, CANCAST

**Robin M. Patel, MD**  
**Mayo Clinic**

Financial Interests or Benefits: Employee of Mayo Clinic

Research funding: BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, The Medicines Company, NIH

Consultant: Curetis, Roche, Diaxonhit, Qvella

Stipends: Journal of Clinical Microbiology, Clinical Infectious Diseases, Manual of Clinical Microbiology

Co-Chair, ASM Microbe Program Planning Committee

Patents: *B. pertussis* and *parapertussis* PCR, anti-biofilm substance, device/method for sonication

Honoraria: USMLE, Up-to-Date, Infectious Diseases Board Review Course, NIH

**Sandra S. Richter, MD, D(ABMM)**  
**Cleveland Clinic**

Financial Interests or Benefits:

Research grants - BD Diagnostics, OpGen, bioMerieux, Nanosphere, Cerexa, Pocared, Biofire Diagnostics, Achaogen Pharmaceuticals, Roche

Speaker honorarium - bioMerieux

Editor stipend - *Journal of Clinical Microbiology*, *Manual of Clinical Microbiology*

**Michael J. Satlin, MD, MS**  
**Weill Cornell Medical College/ NewYork-Presbyterian Hospital**

Financial Interests or Benefits: none

Research grants/contract: Achaogen, Allergan, Merck

**Barbara L. Zimmer, PhD**  
**Beckman Coulter, Inc.**

Financial Interests or Benefits: Employee of Beckman Coulter, Inc. which purchased the Microbiology Business Unit (MicroScan) from Siemens Healthcare Diagnostics 2/1/15

## Advisors

**Vanessa Allen,**  
**Ontario Agency for Health Protection**  
Financial Interests or Benefits: None

**Patricia A. Bradford, PhD**  
**Antimicrobial Development Specialists, LLC**  
Financial Interests or Benefits: Consultant for Adenium, Antabio, Colgate-Polmolive, Contrafect, Entasis, Pontifax, Roche, Tetrphase, Zolex

**William B. Brasso, BS**  
**BD Diagnostic Systems**  
Financial Interests or Benefits: Employee of BD Diagnostic Systems

**Graeme Forrest, MBBS**  
**Portland VA Healthcare System**  
Financial Interests or Benefits: None

**Christian G. Giske, MD, PhD**  
**ESCMID/EUCAST Representative**  
Financial Interests or Benefits: Has received speaker's honoraria from AstraZeneca, Meda, Pfizer, Cepheid, Curetis.

**Howard Gold, MD**  
**Beth Israel Deaconess Medical Center**  
Financial Interests or Benefits: None

**Janet A. Hindler, MCLS, MT(ASCP)**  
**UCLA Health System**  
**APHL**  
Financial Interests or Benefits:  
Speaker's Honoraria: bioMerieux, Inc.; Association of Public Health Labs  
Consultant: Accelerate Diagnostics, Inc.

**Thomas J. Kirn, Jr., MD, PhD**  
**Rutgers Robert Wood Johnson Medical School**  
Financial Interests or Benefits:  
Honorarium - Accelerate Diagnostics, Roche, BD

**Linda A. Miller, PhD**  
**GlaxoSmithKline**  
Financial Interests or Benefits: Employee of GlaxoSmithKline Pharmaceuticals

**Greg Moeck, PhD**  
**The Medicines Company**  
Financial Interests or Benefits: Employee of The Medicines Company

**Sumati Nambiar, MD, MPH**  
**FDA Center for Drug Evaluation and Research**  
Financial Interests or Benefits: None

**David P. Nicolau, PharmD, FCCP, FIDSA**  
**Hartford Hospital**  
Financial Interests or Benefits:  
Consultant, grant recipient and/or on the speaker's bureau for the following entities:  
Achaogen, Allergan, Bayer, Cepheid, Merck, Pfizer, Macrolide Pharmaceuticals, Tetrphase, The Medicines Company, Shionogi.

**Helio S. Sader, MD, PhD**

**JMI Laboratories**

Financial Interests or Benefits: JMI Laboratories, Inc. has also received research and educational grants in 2012-2014 from Achaogen, Actelion, Affinium, American Proficiency Institute (API), AmpliPhi Bio, Anacor, Astellas, AstraZeneca, Basilea, BioVersys, Cardeas, Cempra, Cerexa, Cubist, Daiichi, Dipexium, Durata, Fedora, Forest, Furiex, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Medpace, Meiji Seika Pharma, Melinta, Merck, Methylgene, Nabriva, Nanosphere, Novartis, Pfizer, Polyphor, Rempex, Roche, Seachaid, Shionogi, Synthes, The Medicines Co., Theravance, ThermoFisher, Venatorx, Vertex and Waterloo. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, and Theravance. In regards to speakers bureaus and stock options-none to declare.

**Audrey N. Schuetz, MD, MPH, D(ABMM)**

**Mayo Clinic**

Financial Interests or Benefits: None

**Susan E. Sharp, Ph.D., DABMM, FAAM**

**ASM**

Financial Interests or Benefits: None

**Ribhi M. Shawar, Ph.D, D(ABMM)**

**FDA Ctr. For Devices/Rad. Health**

Financial Interests or Benefits: None

**Pranita Tamma, MD, MHS**

**John Hopkins University School of Medicine**

Financial Interests or Benefits:

Research grant funded jointly by Pfizer and The Joint Commission entitled "What is the Optimal Antimicrobial Stewardship Strategy: Pre-Prescription Authorization or Post-Prescription Review and Feedback?"

Investigator-initiated grant funded by Merck entitled "The effectiveness of piperacillin-tazobactam versus ertapenem for the treatment of intra-abdominal infections involving *Enterococcus faecalis*."

**Kazuhiro Tateda, MD, PhD**

**Toho University School of Medicine**

Financial Interests or Benefits: None

**Maria M. Traczewski, BS, MT(ASCP)**

**The Clinical Microbiology Institute**

Financial Interests or Benefits:

CMI has received research grants/contracts past and present from the following companies:AstraZeneca, Cubist, GlaxoSmithKline, Pfizer, Pfizer Animal Health, Merck, Astellas, Theravance, Novartis, Paratek, Merck Animal Health, Elanco, Cardeas, BioMerieux, Gilead, Intervet, Vertex, Cornerstone Therapeutics, Cerexa, Shering-Plough Vet. Division, MAP Pharmaceuticals, APP Pharmaceuticals, Novoxel, Protez, Leo, Oscient, Achaogen, Trius, Replidyne, Bausch and Lomb, Blanca, Johnson & Johnson, Wyeth, Sanofi-Aventis, Dechra Pharmaceuticals, APP Pharmaceuticals, Symbiomix Therapeutics, Cepheid Inc., Beckman Coulter Healthcare Diagnostics, Advanced Food Technologies, Becton-Dickinson, Stanford University, Dermira Inc. Basilea Pharmaceutica and ContraFect Corp. and Wockhardt Bio AG

**John D. Turnidge, MD**

**Australian Commission for Safety and Quality in Health Care**

Financial Interests or Benefits: None